Loading...
•
Dec 31, 2024
Medifast Q4 2024 Earnings Report
Medifast reported its financial results for the fourth quarter and full year ended December 31, 2024, showing a decrease in revenue and net income compared to the previous year.
Key Takeaways
Medifast announced its fourth quarter and full year 2024 financial results, with Q4 revenue decreasing 37.7% to $119.0 million from $191.0 million in Q4 2023, primarily due to a decrease in active earning OPTAVIA coaches and lower coach productivity. Net income for Q4 2024 was $0.8 million, or $0.07 per diluted share.
Fourth quarter 2024 revenue decreased 37.7% to $119.0 million.
Net income for Q4 2024 was $0.8 million, with diluted EPS of $0.07.
Independent active earning OPTAVIA coaches decreased 34.1% to 27,100.
Cash, Cash Equivalents, and Investment Securities stood at $162.3 million with no debt.
Forward Guidance
The company expects first quarter 2025 revenue to be in the range of $100 million to $120 million and first quarter 2025 EPS to range from a loss of $0.50 per diluted share to $0.00 per diluted share.
Positive Outlook
- Commitment to reestablishing growth across key metrics.
- Focus on driving coach productivity through accelerated customer acquisition.
- Efforts to expand the number of active earning coaches.
- Aim to broaden reach and restore revenue and profitability growth.
- Goal to deliver long-term value to all stakeholders.
Challenges Ahead
- Expected Q1 2025 revenue range of $100 million to $120 million, indicating continued decline.
- Expected Q1 2025 EPS range from a loss of $0.50 to $0.00 per diluted share.
- EPS range excludes any gains or losses from changes in market price of LifeMD common stock investment.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...